December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

25.08 +0.14 (+0.56%)
Streaming Delayed Price Updated: 9:30 AM EDT, Aug 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bicara Therapeutics Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Bicara Therapeutics Q2 Earnings Call Highlights ↗
Bicara Therapeutics (NASDAQ:BCAX) used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of... 
Via MarketBeat
Topics Earnings
Top movers in Friday's after hours session ↗
Via Chartmill
News headline image
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? ↗
This Boston-based biotech, focused on bifunctional antibody therapies for cancer, just reported a notable insider sale in recent filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara (BCAX) Q4 2025 Earnings Transcript ↗
Bicara (BCAX) Q4 2025 Earnings Transcript 
Via The Motley Fool
Bicara Therapeutics (NASDAQ:BCAX) Q1 2026 Results Highlight Clinical Progress as EPS Misses Estimates ↗
Via Chartmill
News headline image
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer ↗
Bicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the... 
Via MarketBeat
News headline image
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet ↗
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back ↗
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data ↗
Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development... 
Via MarketBeat
News headline image
Bicara (BCAX) Q1 2026 Earnings Transcript ↗
Bicara (BCAX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Bicara Therapeutics Q1 Earnings Call Highlights ↗
Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while... 
Via MarketBeat
Topics Earnings
News headline image
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000 ↗
This Boston biotech specializing in antibody therapies for solid tumors reported a notable insider sale during active clinical development. 
Via The Motley Fool
Topics Regulatory Compliance
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? ↗
This Boston biotech focused on bifunctional cancer therapies reported a notable insider sale amid strong one-year stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder. ↗
This Boston biotech innovator in bifunctional cancer therapies reported a notable insider sale, according to recent filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
These stocks that are showing activity before the opening bell on Monday. ↗
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
4 Biotech Stocks Seeing Explosive Momentum Gains ↗
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be... 
Via Benzinga
Topics ETFs Stocks
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On? ↗
Bicara Therapeutics Inc. (NASDAQ: BCAX) shares are trading lower Friday following the release of updated interim data. 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Gold Gains Over 1%; Ross Stores Shares Dip After Pulling Fiscal 2026 Outlook ↗
 
Via Benzinga
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results ↗
 
Via Benzinga
News headline image
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics ↗
The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge. 
Via Investor's Business Daily
News headline image
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Discover the top movers in Friday's pre-market session. ↗
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.